Pharvaris (Nasdaq: PHVS) presented translational, nonclinical, and clinical data on its investigational drug deucrictibant at the Bradykinin Symposium 2026, held Sept. 3-4 in Berlin, Germany.

The presentations covered several areas, including bradykinin science, on-demand therapy, combination treatment, long-term prophylaxis, and cardiovascular safety.

In the Phase 3 RAPIDe-3 trial, a regional subgroup analysis showed that deucrictibant immediate-release (IR) capsule was associated with shorter median time to onset of symptom relief compared with placebo — 1.20 hours in North America and 1.28 hours in Europe and the rest of the world. Complete attack resolution occurred at a median of 11.61 hours and 12.04 hours in those regions, respectively. No serious treatment-related adverse events were reported.

Data from the same trial showed a median time to end of progression of 17.5 minutes with deucrictibant IR capsule versus 228.7 minutes with placebo, with 92.8% of deucrictibant-treated attacks reaching end of progression within 12 hours compared with 60.9% of placebo-treated attacks.

Final data from the Phase 2 CHAPTER-1 open-label extension study showed that participants received deucrictibant for a mean treatment duration of 22.2 months, with maximum exposure reaching 33.8 months. Mean attack rate fell from 2.18 attacks per month at baseline to 0.12 attacks per month during the extension. No serious treatment-related adverse events or treatment-emergent adverse events leading to discontinuation were reported.

Patient-reported outcomes from the CHAPTER-1 extension showed a mean improvement of 26.9 points in Angioedema Quality of Life total scores from baseline at week 86. All participants who reached at least week 86 reported feeling "much better" compared with study baseline.

An integrated cardiovascular safety analysis across Phase 2 and Phase 3 studies found no evidence of QT prolongation, serious arrhythmias, sudden cardiac death, or treatment-related cardiovascular adverse events with deucrictibant.

Deucrictibant has received orphan drug designation from the U.S. Food and Drug Administration, the European Commission, and Swissmedic for the treatment of bradykinin-mediated angioedema.